Viridian Therapeutics, Inc./DE Shareholders' Equity
Viridian Therapeutics, Inc./DE (VRDN) had Shareholders' Equity of $662.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $662.10M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $636.01M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $722.17M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $502.97M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $662.10M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $636.01M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $722.17M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $502.97M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $515.17M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $604.47M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $671.64M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $707.50M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $529.34M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $582.53M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $442.02M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $283.58M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $315.86M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $350.55M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $395.06M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $409.01M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $141.90M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $166.64M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $187.72M 10-K · filed 2025-03-03 | |
| 2021-09-30 | $204.59M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $98.91M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $106.00M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $120.04M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $21.04M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $21.17M 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $27.00M 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $15.75M 10-K · filed 2022-03-11 | |
| 2019-09-30 | $23.17M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $33.44M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $40.96M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $51.34M 10-K · filed 2021-03-26 | |
| 2018-09-30 | $60.72M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $67.67M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $72.71M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $38.51M 10-K · filed 2020-03-13 | |
| 2017-09-30 | $38.98M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $41.34M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $47.99M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | -$61.92M 10-K · filed 2019-03-14 | -$326.00K 10-K · filed 2017-03-24 |
| 2016-09-30 | $4.69M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $6.44M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $8.34M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$45.29M 10-K · filed 2018-03-15 | $10.41M 10-K · filed 2016-03-21 |
| 2015-09-30 | $12.63M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $10.94M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $13.15M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $5.99M 10-K · filed 2017-03-24 | |
| 2014-06-30 | $8.46M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | -$23.89M 10-K · filed 2015-03-27 | -$23.89M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |